
    
      This is a Phase II, open-label, multicenter, prospective study of MGTA-145 + plerixafor
      mobilized HLA-matched sibling and matched unrelated donor allografts for myeloablative
      hematopoietic stem cell transplantation (HSCT) in recipients with hematological malignancies.
      Donors will undergo 1 or 2 days of mobilization and apheresis.
    
  